Maria Kjellsson
Professor at Institutionen för farmaci; Farmakometri
- Telephone:
- +46 18 471 40 09
- E-mail:
- maria.kjellsson@farmaci.uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Maria Kjellsson at Institutionen för farmaci; Farmakometri
Professor at Institutionen för farmaci; Farmakometri
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala - Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Maria Kjellsson at Institutionen för farmaci; Farmakometri
- CV:
- Download CV
- ORCID:
- 0000-0003-3531-9452
More information is available to staff who log in.
Short presentation
Maria Kjellsson is a professor of Pharmacokinetics and an associate professor (Sv. docent) in Pharmacometrics. She is part of the large and successful research unit Pharmacometrics, which is lead by Mats Karlsson.
Biography
Title: Professor in Pharmacokinetics
Position: Professor at the Department of Pharmacy
Research area: Pharmacometric diabetes modelling, Pharmacometric methodology
Research interest:
My research interest is diabetes; mainly type 2, also known as adult on-set diabetes. I co-lead the pharmacometric diabetes group together with Mats Karlsson and we use mixed-effects models to investigate, describe and quantify various time-varying aspects of diabetes, such as disease progression and treatment effects.
Diabetes affects around 285 million people worldwide and due to ageing population, obesity and sedentary life-style, the number of diabetics is likely to increase with 54% by 2030. Apart from the acute feelings of illness elevated glucose levels cause, diabetes also causes long-term complications, including coronary heart disease, blindness and kidney-disease. Diabetes treatment includes life-style changes, such as sugar-reduced diet and exercise but also pharmacological treatment.
What do we do:
The models we are developing span from describing pre-clinical provocations experiments, clinical provocations and HbA1c studies all the way to models describing cardio-vascular disease (CVD) and kidney disease using registry data.
The intended use of the models also varies greatly. Some models would be used by discovery teams in drug industry to translate animal experiments to human studies and pick the best drug dose for humans. Some models are being used in drug development to help optimize clinical study design, perform clinical trial simulations and quantify drug effects. And yet some would be used to predict the long-term gain of a treatment on HbA1c or even the risk of CVD in relation to diabetes.
We are, apart from investigating effects of drug, also investigating the relationship between weight change and insulin sensitivity. Decreased insulin sensitivity is a pre-state of diabetes and understanding the process leading up to diabetes from a whole-body modelling perspective, taking into account genetic information, is also one of our newer research projects.
Publications
Recent publications
- Pharmacometric modeling of drug adverse effects (2023)
- Altered glucose-dependent secretion of glucagon and ACTH is associated with insulin resistance, assessed by population analysis (2023)
- Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1 (2023)
- Optimal dosing of gliclazide-A model-based approach (2023)
- Optimization of trial duration to predict long-term HbA1c change with therapy (2022)
All publications
Articles
- Pharmacometric modeling of drug adverse effects (2023)
- Altered glucose-dependent secretion of glucagon and ACTH is associated with insulin resistance, assessed by population analysis (2023)
- Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1 (2023)
- Optimal dosing of gliclazide-A model-based approach (2023)
- Optimization of trial duration to predict long-term HbA1c change with therapy (2022)
- Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, Assessed with a Semimechanistic Model (2022)
- A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations (2021)
- Optimal Designs for Model-Based Assessment of Insulin Sensitivity and Glucose Effectiveness. (2021)
- Postprandial triglyceride reduction following acute treatment of a selective 5-hydroxytryptamine-2c agonist and characterization using a semi-physiological model (2021)
- Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess (2021)
- Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data (2021)
- An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales (2021)
- Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations (2020)
- Sweet/Fat Preference Taste in Subjects who are Lean, Obese and Very Obese (2020)
- Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response (2020)
- The Integrated Glucose Insulin Minimal Model (2019)
- Translation between two models; Application with integrated glucose homeostasis models (2019)
- Variability Attribution for Automated Model Building (2019)
- Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment (2019)
- Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics (2019)
- A Bounded Integer Model for Rating and Composite Scale Data (2019)
- An exposure-response (ER) model relating nicotine plasma concentration to momentary craving across different nicotine replacement therapy (NRT) formulations (2018)
- Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development (2018)
- Model-Based Residual Post-Processing for Residual Model Identification (2018)
- A Semi-physiological Model of Postprandial Triglyceride Response in Lean, Obese and Very obese Subjects Following a high-fat meal (2018)
- Evidence-Based Design of Fixed-Dose Combinations (2018)
- Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes (2018)
- Model-Based Interspecies Scaling of Glucose Homeostasis (2017)
- Impact of demographics and disease progression on the relationship between glucose and HbA1c (2017)
- Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin (2017)
- Comparison of diagnostics using model-based post-processing for fast automated model building (2017)
- Evidence-based design of fixed-dose combinations (2017)
- Semi-mechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes (2016)
- Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats (2016)
- Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes (2016)
- Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data (2016)
- Requirements for multi-level systems pharmacology models to reach end-usage (2016)
- Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment (2016)
- Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes (2016)
- Mechanistic modeling of hepatic pitavastatin disposition (2016)
- A proof-of-principle example for identifying drug effect from a mechanistic model with a more parsimonious model (2016)
- Interspecies scaling of dynamic glucose and insulin using a mathematical model approach (2015)
- A mathematical disease progression model for the effect of diet and exercise in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study (FDPS) (2015)
- Nonlinear mixed-effects modelling for single cell estimation (2015)
- The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model (2015)
- Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data (2014)
- Modeling of 24-Hour Glucose and Insulin Profiles in Patients With Type 2 Diabetes Mellitus Treated With Biphasic Insulin Aspart (2014)
- Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model (2013)
- A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment (2013)
- ADOPT (A Dynamic HbA(1c) EndpOint Prediction Tool) (2013)
- Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments (2013)
- Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions (2012)
- Abscess penetration of cefpirome (2012)
- Good penetration of moxifloxacin into human abscesses (2012)
- Modeling sleep data for a new drug in development using Markov mixed-effects models (2011)
- Evaluation of the Nonparametric Estimation Method in NONMEM VI (2009)
- The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion (2009)
- Comparison of proportional odds and differential odds models for mixed-effects analysis of categorical data (2008)
- Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM or NLMIXED (2004)
- The effects of dose staggering on metabolic drug-drug interactions (2003)
Books
Conferences
